Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.

@article{Hersh2016ComparativeEA,
  title={Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.},
  author={Carrie M. Hersh and Thomas E. Love and Samuel Cohn and Claire Hara-Cleaver and Robert Bermel and Robert J Fox and Jeffrey A. Cohen and Daniel Ontaneda},
  journal={Multiple sclerosis and related disorders},
  year={2016},
  volume={10},
  pages={44-52}
}
BACKGROUND Dimethyl fumarate (DMF) and fingolimod (FTY) are approved oral disease modifying therapies (DMT) for relapsing multiple sclerosis (MS). Phase 3 trials established these agents as effective and generally well tolerated, though comparative efficacy and discontinuation remain unknown. OBJECTIVE To assess real-world efficacy and discontinuation of DMF and FTY over 12 months in patients with MS. METHODS We identified 458 DMF-treated and 317 FTY-treated patients in a large academic MS… CONTINUE READING
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…